GlassScriptPhysician profile
Sharon Weber
NPI 1184331803
$1,448.86
in general payments reported to CMS, 2019-2025
17 companies · $27.42 in 2025
The $27.42 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $64.48 · 2023: $1,141 · 2024: $216 · 2025: $27.42.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,384.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,384.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $256.27 | 2022-2023 | Ingrezza |
| Alkermes, INC. | $248.55 | 2022-2025 | Aristada, Lybalvi, Vivitrol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $154.43 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $123.11 | 2023 | Austedo |
| E.R. Squibb & Sons, L.L.C. | $121.17 | 2024 | Cobenfy |
| Corium, LLC | $95.77 | 2023 | Azstarys |
| Abbvie INC. | $75.01 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $63.73 | 2023 | Invega Sustenna, Spravato |
| Lundbeck LLC | $52.94 | 2023 | Rexulti |
| Janssen Scientific Affairs, LLC | $50.67 | 2024 | Invega Sustenna |
| Axsome Therapeutics, INC. | $49.13 | 2023 | Auvelity |
| Indivior INC. | $39.93 | 2023 | Perseris |
| Idorsia Pharmaceuticals US INC | $32.10 | 2023 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $27.06 | 2022-2023 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $23.85 | 2023 | Rexulti, Abilify Maintena |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $18.11 | 2023 | Qelbree |
| Ironshore Pharmaceuticals INC. | $17.03 | 2023 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Weber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.